EVOKE PHARMA, INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 9 rows in 2021. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2021-05-13: Reporting owner REED VICKIE S; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2021-05-05: Reporting owner WIDDER KENNETH J; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2021-05-05: Reporting owner RHOADS ANN D; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2021-05-05: Reporting owner Hill Malcolm R; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2021-05-13 | REED VICKIE S Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +70,000 70,000 owned after | $1.14 exercise price | 2021-05-17 | |
| 2021-05-05 | WIDDER KENNETH J Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +56,000 56,000 owned after | $1.55 exercise price | 2021-07-23 | |
| 2021-05-05 | RHOADS ANN D Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +61,750 61,750 owned after | $1.55 exercise price | 2021-07-23 | |
| 2021-05-05 | Hill Malcolm R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +54,000 54,000 owned after | $1.55 exercise price | 2021-07-23 | |
| 2021-05-05 | Brady Todd C Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +57,750 57,750 owned after | $1.55 exercise price | 2021-07-23 | |
| 2021-05-05 | GARNER CAM L Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +67,500 67,500 owned after | $1.55 exercise price | 2021-07-23 | |
| 2021-01-27 | CARLSON MARILYN R. Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +300,000 300,000 owned after | $2.68 exercise price | 2021-01-29 | |
| 2021-01-27 | D'Onofrio Matthew J Officer (Exec VP, Chief Bus. Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +300,000 300,000 owned after | $2.68 exercise price | 2021-01-29 | |
| 2021-01-27 | Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +415,000 415,000 owned after | $2.68 exercise price | 2021-01-29 |